Search Results - "Tyner, Jeffrey W"

The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment by Gotlib, Jason, Maxson, Julia E., George, Tracy I., Tyner, Jeffrey W.

“…Although activation of tyrosine kinase pathways is a shared theme among myeloproliferative neoplasms, the pathogenetic basis of chronic neutrophilic leukemia…”
Get full text

FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia by Traer, Elie, Martinez, Jacqueline, Javidi-Sharifi, Nathalie, Agarwal, Anupriya, Dunlap, Jennifer, English, Isabel, Kovacsovics, Tibor, Tyner, Jeffrey W, Wong, Melissa, Druker, Brian J

“…Potent FLT3 inhibitors, such as quizartinib (AC220), have shown promise in treating acute myeloid leukemia (AML) containing FLT3 internal tandem duplication…”
Get full text

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms by Zhang, Haijiao, Savage, Samantha, Schultz, Anna Reister, Bottomly, Daniel, White, Libbey, Segerdell, Erik, Wilmot, Beth, McWeeney, Shannon K., Eide, Christopher A., Nechiporuk, Tamilla, Carlos, Amy, Henson, Rachel, Lin, Chenwei, Searles, Robert, Ho, Hoang, Lam, Yee Ling, Sweat, Richard, Follit, Courtney, Jain, Vinay, Lind, Evan, Borthakur, Gautam, Garcia-Manero, Guillermo, Ravandi, Farhad, Kantarjian, Hagop M., Cortes, Jorge, Collins, Robert, Buelow, Daelynn R., Baker, Sharyn D., Druker, Brian J., Tyner, Jeffrey W.

“…FLT3 mutations are prevalent in AML patients and confer poor prognosis. Crenolanib, a potent type I pan-FLT3 inhibitor, is effective against both internal…”
Get full text

Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia by Bandyopadhyay, Shovik, Li, Junjie, Traer, Elie, Tyner, Jeffrey W, Zhou, Amy, Oh, Stephen T, Cheng, Ji-Xin

“…Since the advent of tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, and dasatinib, chronic myelogenous leukemia (CML) prognosis has improved…”
Get full text

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia by Carey, Alyssa, Edwards, David K., Eide, Christopher A., Newell, Laura, Traer, Elie, Medeiros, Bruno C., Pollyea, Daniel A., Deininger, Michael W., Collins, Robert H., Tyner, Jeffrey W., Druker, Brian J., Bagby, Grover C., McWeeney, Shannon K., Agarwal, Anupriya

“…Secreted proteins in the bone marrow microenvironment play critical roles in acute myeloid leukemia (AML). Through an ex vivo functional screen of 94…”
Get full text

Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia by Zhang, Haijiao, Nakauchi, Yusuke, Köhnke, Thomas, Stafford, Melissa, Bottomly, Daniel, Thomas, Rozario, Wilmot, Beth, McWeeney, Shannon K, Majeti, Ravindra, Tyner, Jeffrey W

“…Deregulation of the gene family plays an important role in the pathogenesis of acute myeloid leukemia (AML). The BCL2 inhibitor, venetoclax, has received FDA…”
Get full text

Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma by Yuan, Jiang, Jiang, Yan-Yi, Mayakonda, Anand, Huang, Moli, Ding, Ling-Wen, Lin, Han, Yu, Fenggang, Lu, Yanan, Loh, Thomas Kwok Seng, Chow, Marilynn, Savage, Samantha, Tyner, Jeffrey W, Lin, De-Chen, Koeffler, H Phillip

“…Nasopharyngeal carcinoma (NPC) is an invasive cancer with particularly high incidence in Southeast Asia and Southern China. The pathogenic mechanisms of NPC,…”
Get full text

Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia by Bicocca, Vincent T., Chang, Bill H., Masouleh, Behzad Kharabi, Muschen, Markus, Loriaux, Marc M., Druker, Brian J., Tyner, Jeffrey W.

“…We report that t(1;19) ALL cells universally exhibit expression of and dependence on the cell surface receptor ROR1. We further identify t(1;19) ALL cell…”
Get full text

Understanding Drug Sensitivity and Tackling Resistance in Cancer by Tyner, Jeffrey W, Haderk, Franziska, Kumaraswamy, Anbarasu, Baughn, Linda B, Van Ness, Brian, Liu, Song, Marathe, Himangi, Alumkal, Joshi J, Bivona, Trever G, Chan, Keith Syson, Druker, Brian J, Hutson, Alan D, Nelson, Peter S, Sawyers, Charles L, Willey, Christopher D

“…Decades of research into the molecular mechanisms of cancer and the development of novel therapeutics have yielded a number of remarkable successes. However,…”
Get full text

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance by O'Hare, Thomas, Shakespeare, William C., Zhu, Xiaotian, Eide, Christopher A., Rivera, Victor M., Wang, Frank, Adrian, Lauren T., Zhou, Tianjun, Huang, Wei-Sheng, Xu, Qihong, Metcalf, Chester A., Tyner, Jeffrey W., Loriaux, Marc M., Corbin, Amie S., Wardwell, Scott, Ning, Yaoyu, Keats, Jeffrey A., Wang, Yihan, Sundaramoorthi, Raji, Thomas, Mathew, Zhou, Dong, Snodgrass, Joseph, Commodore, Lois, Sawyer, Tomi K., Dalgarno, David C., Deininger, Michael W.N., Druker, Brian J., Clackson, Tim

“…Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain…”
Get full text

Keys to drug sensitivity from updated functional work flows by Kurtz, Stephen E, Tyner, Jeffrey W

Get full text

Kinase Inhibitor Screening in Myeloid Malignancies by Tyner, Jeffrey W., PhD

“…Kinase pathways are primary effectors of many targeted therapy approaches for cancer. Kinase pathways can be dysregulated by mechanisms far more diverse than…”
Get full text

Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance by Javidi-Sharifi, Nathalie, Traer, Elie, Martinez, Jacqueline, Gupta, Anu, Taguchi, Takehiro, Dunlap, Jennifer, Heinrich, Michael C, Corless, Christopher L, Rubin, Brian P, Druker, Brian J, Tyner, Jeffrey W

“…Kinase inhibitors such as imatinib have dramatically improved outcomes for patients with gastrointestinal stromal tumor (GIST), but many patients develop…”
Get full text

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins by Davare, Monika A., Saborowski, Anna, Eide, Christopher A., Tognon, Cristina, Smith, Rebecca L., Elferich, Johannes, Agarwal, Anupriya, Tyner, Jeffrey W., Shinde, Ujwal P., Lowe, Scott W., Druker, Brian J.

“…The rapidly growing recognition of the role of oncogenic ROS1 fusion proteins in the malignant transformation of multiple cancers, including lung…”
Get full text

Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations by Lim, Su Lin, Damnernsawad, Alisa, Shyamsunder, Pavithra, Chng, Wee Joo, Han, Bing Chen, Xu, Liang, Pan, Jian, Pravin, Dakle Pushkar, Alkan, Serhan, Tyner, Jeffrey W, Koeffler, H Phillip

“…Proteolysis targeting chimeric molecule ARV 825 causes ubiquitination of bromodomains resulting in their efficient degradation by proteasome activity…”
Get full text

Gain-of-function mutations in granulocyte colony–stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation by Zhang, Haijiao, Coblentz, Cody, Watanabe-Smith, Kevin, Means, Sophie, Means, Jasmine, Maxson, Julia E., Tyner, Jeffrey W.

“…Granulocyte colony–stimulating factor (G-CSF or CSF3) and its receptor CSF3R regulate granulopoiesis, neutrophil function, and hematopoietic stem cell…”
Get full text

Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia by Leonard, Jessica T, Rowley, Joelle S J, Eide, Christopher A, Traer, Elie, Hayes-Lattin, Brandon, Loriaux, Marc, Spurgeon, Stephen E, Druker, Brian J, Tyner, Jeffrey W, Chang, Bill H

“…Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+)ALL) remains a challenge. Although the addition of targeted tyrosine kinase…”
Get more information

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia by AGARWAL, Anupriya, MACKENZIE, Ryan J, DRUKER, Brian J, PIPPA, Raffaella, EIDE, Christopher A, ODDO, Jessica, TYNER, Jeffrey W, SEARS, Rosalie, VITEK, Michael P, ODERO, Maria D, CHRISTENSEN, Dale J

“…The SET oncoprotein, a potent inhibitor of the protein phosphatase 2A (PP2A), is overexpressed in leukemia. We evaluated the efficacy of SET antagonism in…”
Get full text

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms by Tyner, Jeffrey W., Bumm, Thomas G., Deininger, Jutta, Wood, Lisa, Aichberger, Karl J., Loriaux, Marc M., Druker, Brian J., Burns, Christopher J., Fantino, Emmanuelle, Deininger, Michael W.

“…Activating alleles of Janus kinase 2 (JAK2) such as JAK2V617F are central to the pathogenesis of myeloproliferative neoplasms (MPN), suggesting that small…”
Get full text

DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia by Giacopelli, Brian, Wang, Min, Cleary, Ada, Wu, Yue-Zhong, Schultz, Anna Reister, Schmutz, Maximilian, Blachly, James S, Eisfeld, Ann-Kathrin, Mundy-Bosse, Bethany, Vosberg, Sebastian, Greif, Philipp A, Claus, Rainer, Bullinger, Lars, Garzon, Ramiro, Coombes, Kevin R, Bloomfield, Clara D, Druker, Brian J, Tyner, Jeffrey W, Byrd, John C, Oakes, Christopher C

“…Acute myeloid leukemia (AML) is a molecularly complex disease characterized by heterogeneous tumor genetic profiles and involving numerous pathogenic…”
Get full text